Hot on the heels of finally gaining US Food and Drug Administration approval for its Exondys 51 (eteplirsen), US biotech Sarepta Therapeutics (Nasdaq: SRPT) had entered into a research collaboration with clinical-stage biopharma company Catabasis (Nasdaq: CATB) to explore a combination drug treatment approach for Duchenne muscular dystrophy (DMD).
The two companies will contribute their respective expertise to study an exon-on-skippingskipping treatment developed by Sarepta, together with an oral NF-kB inhibition treatment developed by Catabasis in a mouse model of DMD.
Even though no financial terms were disclosed, news of the collaboration sent Catabasis’ shares rocketing as much as 58% to $7.02, their highest point since June, as the company’s chief executive noted that
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze